Volume 0 - Int J Mol Cell Med (Inprees)                   Int J Mol Cell Med 2025, 0 - Int J Mol Cell Med (Inprees): 0-0 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bahari M, Yeganeh F, Kargar Kheirabad A. Innovative Aptamer-HRP Conjugation for Cardiac Troponin I Detection: A Novel ELASA Approach for AMI Diagnostics. Int J Mol Cell Med 2025;
URL: http://ijmcmed.org/article-1-2492-en.html
1- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences
2- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences , fyeganeh@gmail.com
3- Research and Development of Arghavan Teb Kavian Co
Abstract:   (44 Views)

Acute myocardial infarction (AMI), a major global cause of mortality, is diagnosed using cardiac troponin I (cTnI). Antibody-based assays face challenges, prompting the exploration of aptamers. This study develops an aptamer-HRP probe and ELASA for improved cTnI detection.
Aptamer-based enzyme-linked aptamer assays (ELASA) were developed to detect cTnI using Tro4 and Tro6 aptamers. Molecular docking was performed via the HDOCK web server to confirm aptamer binding affinity to cTnI. Tro4 was biotinylated for use as a capture probe, while Tro6 was conjugated to HRP through sulfo-SMCC crosslinking, followed by size exclusion chromatography and purification. Direct and sandwich ELASA assays were performed using streptavidin-coated plates and clinical serum samples from AMI and non-AMI patients. Data were analyzed using GraphPad Prism10 and SPSS software.
Molecular docking confirmed the high binding affinity of Tro4 and Tro6 aptamers to cTnI, with significant interaction energies. Direct ELASA verified aptamer binding, and optimal concentrations were determined as 10μM for Tro4 and 5μM for Tro6. A sandwich ELASA using paired aptamers achieved improved sensitivity and specificity for cTnI detection. The assay displayed a linear response between 0.1–22 ng.mL cTnI (R²=0.94), with a limit of detection (LOD) of 0.10ng.mL. When tested on patient serum samples, results correlated with a commercial antibody-based ELASA kit.
This study successfully developed a highly sensitive and specific sandwich ELASA for cTnI detection, utilizing the optimal aptamers Tro4 and Tro6. The results demonstrated excellent sensitivity, specificity, and potential clinical applicability, offering a promising alternative to antibody-based assays.

Full-Text [PDF 541 kb]   (34 Downloads)    
Type of Study: Original Article | Subject: Biomarkers (diagnosis & treatment)
Received: 2024/11/26 | Accepted: 2025/03/15 | Published: 2025/12/10

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | International Journal of Molecular and Cellular Medicine IJMCM

Designed & Developed by : Yektaweb